Patent SG-11201806401Y-A (SG)
Title: G protein-coupled receptor (gpcr) modulation by imipridones
Inventor: ALLEN JOSHUA E
IPC: G01N33/566
Filed: 2017-01-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 August 2017 (03.08.2017) WIPO I PCT (10) International Publication Number WO 2017/132661 A3 11111111111111011101111111111101011111011111111011101111111111111011111111111110111111 (51) International Patent Classification: C07K 16/28 (2006.01) CO7D 401/04 (2006.01) C07K 14/705 (2006.01) CO7D 257/04 (2006.01) C07K 14/72 (2006.01) G01N 33/566 (2006.01) (21) International Application Number: PCT/US2017/015608 (22) International Filing Date: 30 January 2017 (30.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/US2016/015817 29 January 2016 (29.01.2016) 62/308,325 15 March 2016 (15.03.2016) 62/425,403 22 November 2016 (22.11.2016) (71) Applicant: ONCOCEUTICS, INC. [US/US]; 3624 Mar- ket Street, Suite 5E, Philadelphia, Pennsylvania 19104 (US). (72) Inventors: ALLEN, Joshua E.; 129 Tremont St, Cam- bridge, Massachusetts 02139 (US). STOGNIEW, Martin; 1870 Ferguson Lane, Blue Pell, Pennsylvania 19422 (US). PRABHU, Varun Vijay; 2375 Woodward St, Phil- adelphia, Pennsylvania 19115 (US). (74) Agents: PEARL COHEN ZEDEK LATZER BARATZ LLP et al.; 1500 Broadway, 12 Floor, New York, New York 10036 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Publ ished: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 31 August 2017 (84) US US US W O 20 17 / 13 266 1 A3 (54) Title: G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES (57) : Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2- like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided.